Cure-focused prizes: pay for verified long-term cures, not for drugs
Governments and philanthropists commit large payments for whoever achieves a verified jump in ten-year cure rates for a specific cancer, however they do it.
Drug incentives reward incremental progression-free survival in late-stage disease; nothing rewards curing. Prize and advance market commitment mechanisms have worked for vaccines and longitude. The proposal is a set of cure prizes, each defined as a verified increase in a specific cancer's five- or ten-year relapse-free survival in a defined population (for example, pancreatic adenocarcinoma stage II, glioblastoma, metastatic triple-negative breast cancer), funded by pooled public and philanthropic commitments, awarded on registry-verified population outcomes with pro-rata payments for partial progress and open licensing conditions.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
Pages like this
not linked directly; found by shared links- IdeaA guaranteed purchase prize for the first drug against a named hard target
Shares Funding follows fashion, not burden, Incentives reward me-too drugs and marginal gains, Pancreatic ductal adenocarcinoma.
- IdeaA billion-dollar prize for the first durable cure of a lethal metastatic cancer
Shares Incentives reward me-too drugs and marginal gains, Glioma & glioblastoma, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma.
- InstitutionEmerson Collective
Shares Funding follows fashion, not burden, Incentives reward me-too drugs and marginal gains.
- IdeaPartial lottery funding for good proposals in under-funded cancers
Shares Funding follows fashion, not burden, Glioma & glioblastoma, Pancreatic ductal adenocarcinoma.
- PersonRandy Pausch
Shares Funding follows fashion, not burden, Pancreatic ductal adenocarcinoma.
- IdeaPay a prize for rare cancer drugs instead of hoping for a market
Shares Funding follows fashion, not burden, Incentives reward me-too drugs and marginal gains.
- PersonMary Lasker
Shares Funding follows fashion, not burden, Incentives reward me-too drugs and marginal gains.
- IdeaJudge funding programme officers on burden alignment and trials completed
Shares Funding follows fashion, not burden, Incentives reward me-too drugs and marginal gains.